-

OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California

The Montana-based compounder commits to supporting prescribers and patients in wake of competitor’s abrupt exit of California market

MISSOULA, Mont.--(BUSINESS WIRE)--OSRX, Inc., a leading provider of compounded ophthalmic medications, announced that the company remains fully licensed, fully operational and continues to serve the needs of California ophthalmologists and optometrists, following a significant market shift involving a major competitor.

“California clinicians and their patients can rely on OSRX for uninterrupted access to high-quality compounded medications,” said Anthony Sampietro, founder and CEO of OSRX.

Share

According to a Feb. 2, 2026 company disclosure, ImprimisRx – the compounding division of Harrow (NASDAQ:HROW) – voluntarily forfeited its California license on February 1 and agreed to pay an administrative fine of approximately $157,000 as part of a settlement agreement reached with the California Board of Pharmacy (CBOP).1 The CBOP previously filed a formal accusation against ImprimisRx in August 2025 outlining multiple causes for discipline.2

This licensing action pertains solely to ImprimisRx and does not affect other 503B outsourcing facilities in good standing with the California Board of Pharmacy, including OSRX.

With many prescribers utilizing compounded ophthalmic medications for post-operative care, glaucoma management, and myopia control, OSRX emphasized its continued operations and the availability of its manufacturing and dispensing services. The FDA-registered and California-licensed 503B outsourcing facility offers a portfolio of compounded ophthalmic formulations and supports both direct‑to‑patient and direct-to-facility dispensing models. OSRX is licensed and operational in all 50 states.

“California clinicians and their patients can rely on OSRX for uninterrupted access to high-quality compounded medications,” said Anthony Sampietro, founder and CEO of OSRX. “We currently support thousands of ophthalmologists and optometrists nationwide and are prepared to assist any practice navigating medication supply changes.”

California prescribers can onboard with OSRX by visiting osrxpharmaceuticals.com or contacting Christina Padilla, West Account Executive, at crpadilla@osrxpharmaceuticals.com or 310-346-6414.

About OSRX

OSRX is an FDA-registered 503B outsourcing facility dedicated to advancing ophthalmic care through high-quality compounded solutions and dedicated customer support for prescribers and patients. Licensed nationwide, the Montana-based company is trusted by more than 10,000 prescribers and is driven by its mission to deliver A New View of Medicine®. Learn more at www.osrxpharmaceuticals.com.

Sources:

  1. [investors.harrow.com]
  2. https://pharmacy.ca.gov/enforcement/accusations/ac227456.pdf

Contacts

Media Contact:
Vanessa Assam-Gorski, Director of Marketing
vmgorski@osrxphamaceuticals.com or 541-944-8531

Industry:

OSRX, Inc.

Release Summary
OSRX remains licensed and operational in California, continuing uninterrupted access to compounded ophthalmic medications.
Release Versions
English

Contacts

Media Contact:
Vanessa Assam-Gorski, Director of Marketing
vmgorski@osrxphamaceuticals.com or 541-944-8531

More News From OSRX, Inc.

OSRX Expands Ophthalmic Solutions with New Medications and Post-Op Kits to Patients’ Doors

MISSOULA, Mont.--(BUSINESS WIRE)--OSRX expands ophthalmic care with new meds & direct-to-patient post-op kits, enhancing workflows & patient access....

OSRX, Inc. Responds to Jury Verdict in Trademark Infringement Case

MISSOULA, Mont.--(BUSINESS WIRE)--OSRX, Inc. today expressed its profound disappointment with the recent jury verdict in the case of ImprimisRx, LLC v. OSRX, Inc. The company believes the decision to be unjust and not based on the facts presented during the trial. Despite this setback, OSRX remains resolute in its commitment to challenge this outcome and address the significant issues that persist. “Leading up to the trial, OSRX won summary judgment on ImprimisRx’s false advertising claims, and...
Back to Newsroom